Inhibition of Xanthine Oxidase Protects against Diabetic Kidney Disease through the Amelioration of Oxidative Stress via VEGF/VEGFR Axis and NOX-FoxO3a-eNOS Signaling Pathway
International Journal of Molecular Sciences · 14.02.2023 · 24 (4) · 3807
DOI: 10.3390/ijms24043807 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 14.02.2023. Verfasst von Keum-Jin Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Institute, Daejeon St. Mary's Hospital, 64, Daeheung-ro, Jung-gu, Daejeon 34943, Republic of Korea. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Xanthine Oxidase. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Catholic Medical Center Research Foundation, Clinical Research Institute of Daejeon St. Mary's Hospital.
Abstract (Originalsprache)
Xanthine oxidase (XO) is an important source of reactive oxygen species. This study investigated whether XO inhibition exerts renoprotective effects by inhibiting vascular endothelial growth factor (VEGF) and NADPH oxidase (NOX) in diabetic kidney disease (DKD). Febuxostat (5 mg/kg) was administered to streptozotocin (STZ)-treated 8-week-old male C57BL/6 mice via intraperitoneal injection for 8 weeks. The cytoprotective effects, its mechanism of XO inhibition, and usage of high-glucose (HG)-treated cultured human glomerular endothelial cells (GECs) were also investigated. Serum cystatin C, urine albumin/creatinine ratio, and mesangial area expansion were significantly improved in febuxostat-treated DKD mice. Febuxostat reduced serum uric acid, kidney XO levels, and xanthine dehydrogenase levels. Febuxostat suppressed the expression of VEGF mRNA, VEGF receptor (VEGFR)1 and VEGFR3, NOX1, NOX2, and NOX4, and mRNA levels of their catalytic subunits. Febuxostat caused downregulation of Akt phosphorylation, followed by the enhancement of dephosphorylation of transcription factor forkhead box O3a (FoxO3a) and the activation of endothelial nitric oxide synthase (eNOS). In an in vitro study, the antioxidant effects of febuxostat were abolished by a blockade of VEGFR1 or VEGFR3 via NOX-FoxO3a-eNOS signaling in HG-treated cultured human GECs. XO inhibition attenuated DKD by ameliorating oxidative stress through the inhibition of the VEGF/VEGFR axis. This was associated with NOX-FoxO3a-eNOS signaling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Research Institute, Daejeon St. Mary's Hospital, 64, Daeheung-ro, Jung-gu, Daejeon 34943, Republic of Korea.
- Division of Nephrology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea.
ORCID-Profile: Won Jung Choi, Yoon-Kyung Chang, Yu Ah Hong
Förderung
- National Research Foundation of Korea
- Catholic Medical Center Research Foundation
- Clinical Research Institute of Daejeon St. Mary's Hospital
- Clinical Research Institute of Daejeon St. Mary’s Hospital
Zitieren
APA
Yang, K. J., Choi, W. J., Chang, Y. K., Park, C. W., Kim, S. Y., & Hong, Y. A. (2023). Inhibition of Xanthine Oxidase Protects against Diabetic Kidney Disease through the Amelioration of Oxidative Stress via VEGF/VEGFR Axis and NOX-FoxO3a-eNOS Signaling Pathway. International Journal of Molecular Sciences, 24(4), 3807. https://doi.org/10.3390/ijms24043807
Vancouver
Yang KJ, Choi WJ, Chang YK, Park CW, Kim SY, Hong YA. Inhibition of Xanthine Oxidase Protects against Diabetic Kidney Disease through the Amelioration of Oxidative Stress via VEGF/VEGFR Axis and NOX-FoxO3a-eNOS Signaling Pathway. International Journal of Molecular Sciences. 2023;24(4):3807. doi:10.3390/ijms24043807
BibTeX
@article{Yang2023,
author = {Yang, Keum-Jin and Choi, Won Jung and Chang, Yoon-Kyung and Park, Cheol Whee and Kim, Suk Young and Hong, Yu Ah},
title = {Inhibition of Xanthine Oxidase Protects against Diabetic Kidney Disease through the Amelioration of Oxidative Stress via VEGF/VEGFR Axis and NOX-FoxO3a-eNOS Signaling Pathway},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {4},
pages = {3807},
doi = {10.3390/ijms24043807}
}
EUVIMED